Literature DB >> 20872224

Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.

Kirstin Dienus1, Ardeshir Bayat, Brendan F Gilmore, Oliver Seifert.   

Abstract

Keloid scars are common benign fibroproliferative reticular dermal lesions with unknown etiology and ill-defined management with high rate of recurrence post surgery. The progression of keloids is characterized by increased deposition of extracellular matrix proteins, invasion into the surrounding healthy skin and inflammation. Fibroblasts are considered to be the key cellular mediators of fibrogenesis in keloid scars. Fibroblast activation protein alpha (FAP-α) and dipeptidyl peptidase IV (DPPIV) are proteases located at the plasma membrane promoting cell invasiveness and tumor growth and have been previously associated with keloid scars. Therefore, in this study we analyzed in further detail the expression of FAP-α in keloid fibroblasts compared to control skin fibroblasts. Dermal fibroblasts were obtained from punch-biopsies from the active margin of four keloids and four control skin samples. Flow cytometry was used to analyze FAP-α expression and the CytoSelect 24-Well Collagen I Cell Invasion Assay was applied to study fibroblast invasion. Secretion of extracellular matrix (ECM) proteins was investigated by multiplexed particle-based flow cytometric assay and enzyme-linked immunosorbent assay. We found an increased expression of FAP-α in keloid fibroblasts compared to control skin fibroblasts (p < 0.001). Inhibition of FAP-α/DPPIV activity using the irreversible inhibitor H(2)N-Gly-Pro diphenylphosphonate reduced the increased invasiveness of keloid fibroblasts (p < 0.001) indicating that keloid invasion may be partly FAP-α/DPPIV mediated. FAP-α/DPPIV inhibition had no effect, (a) on the synthesis of the ECM proteins procollagen type I C-terminal peptide and fibronectin, (b) on the production of fibroblast growth factor or vascular endothelial growth factor, (c) on the expression of the proinflammatory cytokines interleukin-6 (IL-6), interleukin 8 (IL-8) or monocyte chemotactic protein-1. These results suggest a potential role for FAP-α and DPPIV in the invasive behavior of keloids. FAP-α and DPPIV may increase the invasive capacity of keloid fibroblasts rather than by modulating inflammation or ECM production. Since FAP-α expression is restricted to reactive fibroblasts in wound healing and normal adult tissues are generally FAP-α negative, inhibiting FAP-α/DPPIV activity may be a novel treatment option to prevent keloid progression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872224     DOI: 10.1007/s00403-010-1084-x

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  18 in total

Review 1.  Novel pharmacotherapy for burn wounds: what are the advancements.

Authors:  Michael R Hamblin
Journal:  Expert Opin Pharmacother       Date:  2018-12-05       Impact factor: 3.889

2.  Side effects of frequently used oral antidiabetics on wound healing in vitro.

Authors:  Ewa Klara Stuermer; M Besser; N Terberger; V Koester; H S Bachmann; A L Severing
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-07       Impact factor: 3.000

Review 3.  The role of fibroblast activation protein in health and malignancy.

Authors:  Allison A Fitzgerald; Louis M Weiner
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

Review 4.  New molecular medicine-based scar management strategies.

Authors:  Anna I Arno; Gerd G Gauglitz; Juan P Barret; Marc G Jeschke
Journal:  Burns       Date:  2014-01-15       Impact factor: 2.744

5.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold.

Authors:  Koen Jansen; Leen Heirbaut; Jonathan D Cheng; Jurgen Joossens; Oxana Ryabtsova; Paul Cos; Louis Maes; Anne-Marie Lambeir; Ingrid De Meester; Koen Augustyns; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2013-03-18       Impact factor: 4.345

6.  Effects of Prisma® Skin dermal regeneration device containing glycosaminoglycans on human keratinocytes and fibroblasts.

Authors:  Raffaella Belvedere; Valentina Bizzarro; Luca Parente; Francesco Petrella; Antonello Petrella
Journal:  Cell Adh Migr       Date:  2017-08-10       Impact factor: 3.405

7.  The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

Authors:  Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-19       Impact factor: 9.236

8.  In Vitro Differentiation Potential of Human Placenta Derived Cells into Skin Cells.

Authors:  Ruhma Mahmood; Mahmood S Choudhery; Azra Mehmood; Shaheen N Khan; Sheikh Riazuddin
Journal:  Stem Cells Int       Date:  2015-07-01       Impact factor: 5.443

9.  Characterization of dedifferentiating human mature adipocytes from the visceral and subcutaneous fat compartments: fibroblast-activation protein alpha and dipeptidyl peptidase 4 as major components of matrix remodeling.

Authors:  Julie Lessard; Mélissa Pelletier; Laurent Biertho; Simon Biron; Simon Marceau; Frédéric-Simon Hould; Stéfane Lebel; Fady Moustarah; Odette Lescelleur; Picard Marceau; André Tchernof
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

10.  Validated prediction of pro-invasive growth factors using a transcriptome-wide invasion signature derived from a complex 3D invasion assay.

Authors:  Bettina Oehrle; Gerald Burgstaller; Martin Irmler; Stefan Dehmel; Jessica Grün; Tiffany Hwang; Susanne Krauss-Etschmann; Johannes Beckers; Silke Meiners; Oliver Eickelberg
Journal:  Sci Rep       Date:  2015-08-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.